# Data Sheet (Cat.No.T75129)

TargetMol

## Luxdegalutamide

### Chemical Properties



CAS No. : 2750830-09-0

Formula: C45H54FN7O6

Molecular Weight: 807.95

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Luxdegalutamide (ARV-766) is a PROTAC and a protein degrader targeting the androgen receptor, capable of effectively degrading wild-type and drug-resistant mutants including L702H, H875Y, and T878A. With oral bioactivity and cell permeability, this compound is used in castration-resistant prostate cancer research and exhibits significant antitumor activity. |
| Targets(IC50) | Androgen Receptor,PROTACs |
| In vitro | **Methods**: Human primary hepatocytes were treated with various concentrations of Luxdegalutamide (0.03-30 μM) for 48 hours, and mRNA expression levels of CYP1A2, 2B6, 2C9, 2C8, and CYP3A4 were detected.<br>**Results**: Luxdegalutamide induced CYP3A4 and CYP2C8 mRNA expression, but did not induce CYP1A2, 2B6, or 2C9 mRNA expression, indicating that this drug essentially does not cause cytochrome P450 (CYP) and transporter-mediated drug-drug interactions (DDI). [1] |
| In vivo | Luxdegalutamide (ARV-766) significantly and dose-dependently inhibits tumor growth in mouse LNCaP and VCaP xenograft models.[2] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 250 mg/mL (309.43 mM)<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.2377 mL | 6.1885 mL | 12.377 mL |
| 5 mM | 0.2475 mL | 1.2377 mL | 2.4754 mL |
| 10 mM | 0.1238 mL | 0.6189 mL | 1.2377 mL |
| 50 mM | 0.0248 mL | 0.1238 mL | 0.2475 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Snyder L, et al. In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450-and transporter-mediated drug-drug interaction[J]. Drug Metabolism and Pharmacokinetics, 2024, 55: 100881.
Snyder L, et al. Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer[J]. Cancer Research, 2023, 83(7_Supplement): ND03-ND03.